Captopril

See Contraindications. Increased risk of angioedema with concomitant neprilysin inhibitor or mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K⁺-sparing diuretics, K⁺ supplements and K⁺-containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function in elderly and/or volume depleted). Potentiated by, and hypotension with diuretics, β-blockers, adrenergic antagonists. Discontinue nitroglycerin, other nitrates, or other vasodilators before starting therapy; if resumed, reduce dose and give cautiously. May increase lithium levels. May produce false (+) urinary acetone. Nitritoid reactions with injectable gold (eg, sodium aurothiomalate); rare.

See Contraindications. Increased risk of angioedema with concomitant neprilysin inhibitor or mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K⁺-sparing diuretics, K⁺ supplements and K⁺-containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function in elderly and/or volume depleted). Potentiated by, and hypotension with diuretics, β-blockers, adrenergic antagonists. Discontinue nitroglycerin, other nitrates, or other vasodilators before starting therapy; if resumed, reduce dose and give cautiously. May increase lithium levels. May produce false (+) urinary acetone. Nitritoid reactions with injectable gold (eg, sodium aurothiomalate); rare.

See Contraindications. Increased risk of angioedema with concomitant neprilysin inhibitor or mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K⁺-sparing diuretics, K⁺ supplements and K⁺-containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function in elderly and/or volume depleted). Potentiated by, and hypotension with diuretics, β-blockers, adrenergic antagonists. Discontinue nitroglycerin, other nitrates, or other vasodilators before starting therapy; if resumed, reduce dose and give cautiously. May increase lithium levels. May produce false (+) urinary acetone. Nitritoid reactions with injectable gold (eg, sodium aurothiomalate); rare.